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Abstract. The keto-enol type tautomerism in anti-thyroid drugs and their selenium analogues are de-
scribed. The commonly used anti-thyroid drug methimazole exists predominantly in its thione form, 
whereas its selenium analogue exists in a zwitterionic form. To understand the effect of thione/thiol and 
selone/selenol tautomerism on the inhibition of peroxidase-catalysed reactions, we have synthesized some 
thiones and selones in which the formation of thiol/selenol forms are blocked by different substituents. These 
compounds were synthesized by a carbene route utilizing an imidazolium salt. The crystal structures of 
these compounds reveal that the C=Se bonds in the selones are more polarized than the C=S bonds in the 
corresponding thiones. The structures of selones were studied in solution by NMR spectroscopy and the 
77Se NMR chemical shifts for the selones show large upfield shifts in the signals, confirming their zwit-
terionic structures in solution. The inhibition of lactoperoxidase by the synthetic thiones indicates that the 
presence of a free N-H moiety is essential for an efficient inhibition. In contrast, such moiety is not re-
quired for an inhibition by the selenium compounds. 
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1. Introduction 
The heme peroxidase superfamily of ‘mammalian 
peroxidases’ include lactoperoxidase (LPO), mye-
loperoxidase (MPO), eosinophil peroxidase (EPO) 
and thyroid peroxidase (TPO), which catalyse several 
important biological reactions.1 Thyroid peroxidase 
(TPO), in particular, involves in the biosynthesis of 
the thyroid hormone, thyroxine (T4). The synthetic 
routes for thyroxine generation in thyroid gland 
catalysed by TPO involve two distinct reactions: io-
dination of tyrosyl residues in tyroglobulin (Tg) and 
phenolic coupling of the resulting iodinated tyrosyl 
residues.2 The first step in the thyroid hormone bio-
synthesis is the oxidation of the iron center in the 
native enzyme by hydrogen peroxide to form com-
pound I that exist in two different forms: an oxoferryl 
protein radical and an oxoferryl porphyrin pi-cation 
radical. In the presence of reducing agents such as 
iodide and thyroglobulin, iodide is rapidly oxidized 
by π-cation radical to an iodinating species that is 
involved in the iodination of the tyrosyl residues on 
Tg. The coupling reaction occurs simultaneously 
with iodination by the π-cation radical (figure 1). 
 The prohormone T4, produced by the TPO/ 
H2O2/I
– system, is then converted to its biologically 
active form T3 by an outer ring de-iodination path-
way. This particular reaction is catalysed by an io-
dothyronine deiodinase (ID-I), which is present in 
highest amounts in liver, kidney, thyroid and pitui-
tary.3 The thyroid gland also produces an inactive  
metabolite rT3 by an inner ring deiodination path-
way. The triiodo derivatives T3 and rT3 are further 
 
 
 
 
Figure 1. Synthesis of thyroid hormones by heme-
containing thyroid peroxidase (TPO). 
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metabolized by inner ring and outer ring de-iodination, 
respectively, by ID-I, and two other iodothyronine 
deiodinases called ID-II and ID-III to produce the 
inactive metaboilite T2 (3,3′-T2, 3,5-T2 and 3′,5′-
T2). The outer ring 5'-de-iodination catalysed by the 
ID-I enzyme is considered to be the first step in thy-
roid hormone action, because this is the only de-
iodination pathway that leads to the formation of an 
active thyroid hormone.3 
 Although the iodination and de-iodination reac-
tions are essential for the function of thyroid gland, 
the activation of thyroid stimulating hormone (TSH) 
receptor by auto-antibodies leads to an overproduc-
tion of thyroid hormones. As these antibodies are 
not under pituitary feedback control system, there is 
no negative influence on the thyroid activity and, 
therefore, the uncontrolled production of thyroid 
hormones leads to a condition called ‘hyperthyroid-
ism’.3 The overproduction of T4 and T3 can be con-
trolled by blocking the thyroid hormone biosynthesis 
or reducing the conversion of T4 to T3. The thio-
urea drugs such as methimazole (1, MMI), 6-n-
propyl-2-thiouracil (3, PTU), and 6-methyl-2-thiouracil 
(5, MTU) are generally employed for reducing the 
thyroid hormone level (figure 2). Although the pre-
cise mechanism of their action is not known, these 
compounds have been shown to reduce the forma-
tion of thyroxine by inhibiting the TPO enzyme.4 
MMI has been found to be particularly effective and 
this imidazole-based compound normally leads to an 
irreversible inhibition of the enzyme. The thiourea-
based compounds PTU (3) and MTU (5) also inhibit 
the TPO activity, but their action on the enzyme is 
not completely irreversible. 
 
 
 
 
Figure 2. Chemical structures of some anti-thyroid 
drugs and their analogues. 
 In recent years, the selenium analogues of MMI 
(2, MSeI), PTU (4, PSeU) and MTU (6, MSeU) at-
tracted considerable attention.5,6 The selenium ana-
logues may exhibit much higher inhibitory activity 
towards TPO as compared with their sulfur ana-
logues due to their high nucleophilic character. In 
addition to their inhibitory action, the selenium ana-
logues may have significant effect on the hydrogen 
peroxide and other reactive oxygen species. The 
degradation of the intracellular hydrogen peroxide 
by the selenium analogues of anti-thyroid drugs may 
be beneficial to the thyroid gland as these com-
pounds may act as antioxidants and protect thyroid 
cells from oxidative damage. In this regard, our 
group is working on the mechanism of the inhibition 
of peroxidase-catalysed oxidation and iodination re-
actions by anti-thyroid drugs and their selenium ana-
logues. Recently, we have shown that the selenium 
analogue of MMI (i.e. MSeI) is unstable and this 
compound oxidizes spontaneously to produce the 
corresponding diselenide.6 In this paper, we describe 
the importance of the thione moiety in anti-thyroid 
agents and the effect of thiol/thione and selenol/ 
selone tautomerism on peroxidase-catalysed oxida-
tion reactions. 
2. Experimental 
2.1 General procedure 
Lactoperoxidase from bovine milk and ABTS (2,2′-
azino-bis 3-ethylbensthiazoline sulfonic acid) were 
purchased from Fluka Chemical Co. n-Butyllithium 
was purchased from Acros Chemical Co. (Belgium). 
Sodium borohydride (NaBH4), benzyl chloride, suph-
fur and selenium powder were obtained from Al-
drich. The anti-thyroid drugs 2-mercapto-1-methyl-
imidazole 1; 6-n-propyl-2-thiouracil 3; 6-methyl-2-
uracil 5 were obtained from TCI (Tokyo Kasei, Japan) 
company. All other chemicals were of the highest 
purity available. All experiments were carried out 
under dry and oxygen free argon/nitrogen using 
standard Schlenk techniques for the synthesis. Due 
to unpleasant odors of several of the reaction mix-
tures involved, most manipulations were carried out 
in a well-ventilated fume hood. Melting points were 
determined in open tubes on a Buchi melting point 
B-540 apparatus and are uncorrected. Mass spectral 
(MS) studies were carried out on a Q-TOF Micro 
mass spectrometer with electrospray ionization MS 
mode analysis. In the case of isotopic patterns, the 
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value given is for the most intense peak. Elemental 
analyses were performed on a ThermoFinigan FLASH 
EA 1112 CHNS analyser. Liquid state NMR spectra 
were recorded in CDCl3 as a solvent. 
1H (400 MHz), 
13C (100 MHz) and 77Se (76⋅3 MHz) NMR spectra 
were obtained on a Bruker Avance 400 NMR Spec-
trometer using the solvent as an internal standard for 
1H and 13C. Chemical shifts (1H, 13C) are cited with 
respect to tetramethylsilane (TMS). The 77Se NMR 
spectra were recorded using diphenyl diselenide as 
an external standard. The 77Se NMR chemical shifts 
are reported relative to dimethyl selenide (0 ppm) by 
assuming that the resonance of the standard is at 
461⋅0 ppm. In most of the cases, the 77Se NMR ex-
periments were run overnight to obtain good quality 
spectra. Thin-layer chromatography analyses were 
carried out on pre-coated silica gel plates (Merck) 
and spots were visualized by UV irradiation. Col-
umn chromatography was performed on glass col-
umns loaded with silica gel or on automated flash 
chromatography system (Biotage) by using pre-loaded 
silica cartridges. High performance liquid chroma-
tography (HPLC) experiments were carried out on a 
Waters Alliance System (Milford, MA) consisting of 
a 2690 separation module, a 2690 photodiode-array 
detector and a fraction collector. The assays were 
performed in 1⋅8 mL sample vials and a built-in auto-
sampler was used for sample injection. The Alliance 
HPLC System was controlled with EMPOWER 
software (Waters Corporation, Milford, MA). 
 
2.1a Synthesis of 1-benzyl-1H-imidazole: A mix-
ture of imidazole (3⋅26 g, 0⋅048 mol), benzyl chloride 
(6⋅08 g, 0⋅048 mol) and four equivalents of sodium 
hydride (60%; 7⋅68 g, 0⋅19 mol) was refluxed over-
night in dry THF (50 mL) under nitrogen atmos-
phere. The solvent was removed completely under 
vacuum. The resulting residue was treated with water 
(30 mL) and dichloromethane (30 mL), the organic 
layer was washed two more times with water to re-
move the excess sodium hydride, and then separated 
and dried it over anhydrous sodium sulfate. The sol-
vent was removed completely under vacuum to give 
a pale yellow solid. This was washed with petroleum 
ether to remove the non-polar impurities, the residue 
was dried under vacuum to afford a pale yellow 
solid. Yield: 6⋅21 g, 82%⋅ m.p. 71–73°C. 1H NMR 
(CDCl3, ppm): δ = 5⋅12 (s, 2H of PhCH2), 6⋅90 (s, 
1H, NCH of imidazole ring), 7⋅09 (s, IH, NCH of 
imidazole ring), 7⋅27 (m, 5H, CH of benzene ring), 
7⋅56 (s, 1H, NCH); 13C NMR (CDCl3, ppm): 
δ = 50⋅9 (CH2Ph), 119⋅4, 136⋅2 (C of imidazole), 
127⋅3, 128⋅3, 129⋅0, 129⋅9, (C of benzene ring), 
137⋅4 (NCN of imidazole ring). 
 
2.1b Synthesis of-1-benzyl-3-ethyl-1H-imidazole-
2(3H)-thione (7): 1-Benzylimidazole (0⋅2 g, 1⋅26 mmol) 
was dissolved in 10 mL of ethyl acetate in a 50 mL 
two-neck round bottom flask fitted with a reflux 
condenser. To the solution, ethyl bromide (0⋅1 mL, 
1⋅26 mmol) was added drop-wise. This reaction mix-
ture was refluxed for 24 h, and then the solvent was 
removed under vacuum to get a pale yellow solid. 
The solid obtained in the first step was taken in a 
50 mL two-neck round bottom flask fitted with a re-
flux condenser and was added dry methanol 
(25 mL). The resulting solution was treated with sul-
fur powder (0⋅04 g, 1⋅26 mmol) and anhydrous po-
tassium carbonate (0⋅16 g, 1⋅15 mmol). The reaction 
mixture was heated to reflux for 24 h. The solution 
was then filtered through a pad of Celite and washed 
two times with dry methanol. The small impurities 
in the sample can be removed by column chroma-
tography (silica gel) by using 1 : 1 ethyl acetate: pe-
troleum ether. Yield: 0⋅13 g (47%). m.p. 87–89°C. 1H 
NMR (CDCl3, ppm): δ = 1⋅39 (t, 3H, JH–H = 7⋅2 Hz, 
of NCH2CH3), 4⋅13 (q, 2H, JH-H = 7⋅2 Hz, of NCH2), 
5⋅26 (s, 2H, NCH2), 6⋅56 (d, IH, JH–H = 2 Hz, C–H 
of imidazole ring), 6⋅68 (d, IH, JH–H = 2⋅4 Hz, C–H 
of imidazole ring), 7⋅33 (m, 5H, CH of benzene 
ring); 13C NMR (CDCl3, ppm): δ = 13⋅2 (CH3), 41⋅9 
(CH2 of ethyl group), 50⋅1 (CH2Ph), 115⋅1, 115⋅5 
(CH of imidazole ring), 127⋅1, 127⋅3, 127⋅8, 134⋅8 
(CH of benzene ring), 161⋅1 (C=S of imidazole 
ring). 
 
2.1c Synthesis of-1-benzyl-3-ethyl-1H-imidazole-
2(3H)-selone (8): 1-Benzylimidazole (0⋅2 g, 1⋅26 mmol) 
was dissolved in 10 mL of ethyl acetate in a 50 mL 
two-neck round bottom flask fitted with a reflux 
condenser. To the solution, ethyl bromide (0⋅1 mL, 
1⋅26 mmol) was added drop-wise. This solution was 
refluxed for 24 h, and then the solvent was removed 
under vacuum to give a pale yellow solid. The solid 
obtained in the first step was taken in a 50 mL two-
neck round bottom flask fitted with a reflux con-
denser and was added dry methanol (25 mL). The 
resulting solution was treated with activated sele-
nium powder (0⋅1 g, 1⋅26 mmol) and anhydrous po-
tassium carbonate (0⋅16 g, 1⋅15 mmol). The reaction 
mixture was heated to reflux for 24 h. The solution 
was then filtered through a pad of celite to remove 
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the unreacted selenium and washed with methanol. 
The small impurities in the sample can be removed 
by column chromatography (silica gel) by using 1 : 1 
ethyl acetate: petroleum ether. Yield: 0⋅16 g (47%). 
m.p. 92–94°C. 1H NMR (CDCl3, ppm): δ = 1⋅41 (t, 
3H, JH–H = 7⋅2 Hz, of NCH2CH3), 4⋅23 (q, 2H, JH–H = 
7⋅2 Hz, NCH2), 5⋅36 (s, 2H, NCH2), 6⋅73 (d, IH, JH–H = 
2 Hz, C–H of imidazole ring), 6⋅86 (d, IH, JH–H = 
2⋅4 Hz, C–H of imidazole ring), 7⋅34 (m, 5H, CH of 
benzene ring); 13C NMR (CDCl3, ppm): δ = 13⋅5 
(CH3), 43⋅9 (CH2 of ethyl group), 51⋅9 (CH2Ph), 
117⋅3, 117⋅7, (CH of imidazole ring), 127⋅3, 127⋅4, 
127⋅9, 134⋅5 (CH of benzene ring), 154⋅5 (C=Se of 
imidazole ring); 77Se NMR (CDCl3, ppm): δ = –9; 
Elemental analysis: Anal. Calcd. for C12H14N2Se: C, 
54⋅34; H, 5⋅32; N, 10⋅56 Found: C, 54⋅49; H, 5⋅51; 
N, 10⋅49. 
 
2.1d Synthesis of 1,3-dibenzyl-1H-imidazole-2(3H)- 
thione (9): Benzyl chloride (0⋅8 mL, 6⋅96 mmol) 
was added to a two-neck flask containing sodium 
iodide (1⋅04 g, 6⋅96 mmol) and 1-benzylimidazole 
(1⋅0 g, 6⋅33 mmol) in 20 mL acetone. The reaction 
mixture was stirred for 6 h at room temperature. The 
solvent was removed under vacuum and the result-
ing residue was treated with dichloromethane. The 
mixture was stirred for 5 min and the precipitated 
sodium chloride was removed by filtration. The sol-
vent dichloromethane was evaporated under reduced 
pressure to yield a yellow solid, which was used for 
the next step without any further purification. The 
yellow solid obtained in the first step was taken in a 
100 mL two-neck round bottom flask fitted with a 
reflux condenser and was added dry methanol 
(30 mL). The resulting slurry was treated with sulfur 
powder (0⋅2 g, 6⋅33 mmol) and anhydrous potassium 
carbonate (0⋅8 g, 5⋅80 mmol). The reaction mixture 
was heated to reflux for 8 h. The solution was then 
filtered in hot condition through a pad of Celite and 
washed two times with dry methanol. The desired 
compound was obtained as a white crystalline solid. 
The small impurities in the sample can be removed 
by column chromatography (silica gel) using 1 : 5 
ethyl acetate: petroleum ether. Yield: 0⋅80 g (45%). 
m.p.103–105°C. 1H NMR (CDCl3, ppm): δ = 5⋅30 
(s, 4H of NCH2Ph), 6⋅54 (s, 2H, NCH), 7⋅33 (m, 
10H, CH of benzene ring); 13C NMR (CDCl3, ppm): 
δ = 51⋅4 (NCH2Ph), 116⋅8 (CH of imidazole ring), 
128⋅2, 128⋅4, 128⋅9, 135⋅9 (CH of benzene ring), 
163⋅2 (C=S of imidazole ring); HRMS m/z (TOF) 
calcd. for C17H16N2S [M + Na]
+ 303⋅0932, found 
303⋅0930; Elemental analysis: Anal. calcd. for 
C17H16N2S: C, 72⋅82; H, 5⋅75; N, 9⋅99 Found: C, 
72⋅74; H, 6⋅0; N, 10⋅09. 
 
2.1e Synthesis of 1,3-dibenzyl-1H-imidazole-2(3H)- 
selone (10): Benzyl chloride (0⋅8 mL, 6⋅96 mmol) 
was added to a two-neck flask containing sodium 
iodide (1⋅04 g, 6⋅96 mmol) and 1-benzylimidazole 
(1⋅0 g, 6⋅33 mmol) in 20 mL acetone. The reaction 
mixture was stirred for 6 h at room temperature. The 
solvent was removed under vacuum and the result-
ing residue was treated with dichloromethane. The 
mixture was stirred for 5 min and the precipitated 
sodium chloride was removed by filtration. The sol-
vent dichloromethane was evaporated under reduced 
pressure to yield a yellow solid, which was used for 
the next step without any further purification. The 
yellow solid obtained in the first step was taken in a 
100 mL two-neck round bottom flask fitted with a 
reflux condenser and was added dry methanol 
(30 mL). The resulting slurry was treated with acti-
vated selenium powder (0⋅5 g, 6⋅33 mmol) and an-
hydrous potassium carbonate (0⋅8 g, 5⋅80 mmol). 
The reaction mixture was heated to reflux for 8 h. 
The solution was then filtered in hot condition 
through a pad of Celite and washed two times with 
dry methanol. The desired compound was obtained 
as a white crystalline solid. The small impurities in 
the sample can be removed by column chromatography 
(silica gel) by using 1 : 5 ethyl acetate: petroleum 
ether. Yield: 0⋅85 g (40%). m.p. 112–114°C. 1H 
NMR (CDCl3, ppm): δ = 5⋅38 (s, 4H of NCH2Ph), 
6⋅87 (s, 2H, NCH), 7⋅33 (m, 10H, CH of benzene 
ring); 13C NMR (CDCl3, ppm): δ = 53⋅4 (NCH2Ph), 
118⋅9 (CH of imidazole ring), 128⋅4, 128⋅5, 129⋅0, 
135⋅5 (CH of benzene ring), 157⋅1 (C=Se of imida-
zole ring); 77Se NMR (CDCl3, ppm): δ = 0. HRMS 
m/z (TOF) calcd for C17H16N2Se [M + Na]
+ 351⋅0376, 
found 351⋅0374; Elemental analysis: Anal. calcd. C, 
62⋅39; H, 4⋅93; N, 8⋅56 Found: C, 62⋅31; H, 4⋅85; N, 
8⋅63. 
 
2.1f LPO-catalysed oxidation: The LPO inhibition 
experiments were performed in phosphate buffer 
(pH 7⋅0) at 25°C. The spectral measurements were 
carried out on a UV-Vis spectrophotometer and the 
assay of LPO enzyme activity was followed by cata-
lysis of the oxidation of ABTS. The initial rate for 
the oxidation reaction was calculated by following 
UV absorption increase at 411 nm. Enzyme activity 
after the addition of various inhibitors was expressed 
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as the percentage of that observed in the absence of 
inhibitors. The peroxide concentration was always 
present in excess with respect to enzyme. The inhi-
bition plots were obtained by using Origin 6.1 soft-
ware and these plots were used for the calculation of 
the IC50 values. In a typical experiment, 100 mM 
ABTS (used as diammonium salt) and 30 mM hy-
drogen peroxide (from 30% w/w solution) solutions 
were freshly prepared in deionized water. Lactoper-
oxidase enzyme solution containing 0⋅15–0.25 unit/mL 
was prepared in cold deionized water and used im-
mediately for the assay. In a 1 mL reaction mixture, 
the final concentrations are 12⋅9 nM LPO, 28⋅7 μM 
H2O2, 1⋅4 mM ABTS and 1–200 mM inhibitor. For 
the compounds that are not soluble in buffer, a 
minimum amount of DMSO (~10 μL) and diluted 
with the test buffer. Likewise the control reactions 
were carried out with the same amount of DMSO. 
 
2.1g Single crystal X-ray crystallography: X-ray 
crystallographic studies were carried out on a Bruker 
CCD diffractometer with graphite-monochromatized 
Mo-Kα radiation (λ = 0⋅71073 Å) controlled by a 
Pentium-based PC running on the SMART software 
package. (Bruker AXS: Madison, WI). Single crys-
tals were mounted at room temperature on the ends 
of glass fibres and data were collected at room tem-
perature. The structures were solved by direct meth-
ods and refined using the SHELXTL software 
package (Siemens Industrial Automation Inc.: Madi-
son, WI).24 In general, all non-hydrogen atoms were 
refined anisotropically. Hydrogen atoms were as-
signed idealized locations. Empirical absorption cor-
rections were applied to all structures using SADABS. 
(Siemens Industrial Automation Inc.: Madison, 
WI).25,26 
3. Results and discussion 
3.1 Thiol/thione and selenol/selone tautomerism 
The keto-enol type tautomerism in the anti-thyroid 
drugs and their selenium analogues has been a focus 
of several investigations.7 It is known that the anti-
thyroid agent MMI (1) exists almost exclusively as 
the thione tautomer, which is important for the inhi-
bition of thyroid hormone synthesis. The other sul-
fur-containing drugs, PTU (4) and MTU (6) have also 
been shown to exist as the thione tautomers.7 The 
stability of the thione tautomer may prevent these 
compounds from being oxidized spontaneously to 
their corresponding disulfides, which may account 
for their high anti-thyroidal activity. Laurence et al 
have shown that the thione tautomer of MMI is res-
ponsible for its complexation with diiodine and the 
iodine complex of the thione tautomer 1a is favoured 
by 13⋅2 kJ mol–1 compared to that of the thiol tautomer 
1b.7g Therefore, the facile oxidation of 2 to the cor-
responding diselenide requires the compound to be 
in its selenol form (2b) and not in the selone form 
(2a) (figure 3). Although compound 2 can exist in 
both selenol and selone forms in solution, the 77Se 
NMR spectrum recorded immediately after the workup 
of the reaction showed a signal at 4 ppm, which 
cannot be ascribed to the true selone (2a) or undis-
sociated selenol (2b) tautomer, but it can be ascribed 
to a species with more negative charge on selenium 
(2c). In the presence of air, this species slowly oxi-
dizes to the corresponding diselenide, which shifts 
the equilibrium from a selone to a dissociated selenol, 
and this process continues until all the selone–sele-
nolate mixture is converted to diselenide.6b In con-
trast, the sulfur analogue, which exists predomi-
nantly in its thione tautomer form (1a), was found to 
be stable under normal atmosphere. 
 The synthesis of the selenium analogue of methi-
mazole (2, MSeI) was first described by Guziec et 
al.
5d In this case, the authors have mentioned that 
their initial attempts to synthesize MSeI by an alky-
lation-selenation sequence, commonly employed for 
the preparation of acyclic selenoureas, did not afford 
the desired selone. However, an alternative approach 
involving low temperature metallation of 1-methyl-
imidazole, followed by selenium insertion afforded 
the desired compound in moderate yield.5d This 
methodology was recently employed by Parkin et al 
to synthesize 1-mesityl-1,3-dihydro-imidazole-2-
selone.8 It should be mentioned that the replacement 
of N–H moiety in MMI with an N–Me group has 
been shown to abolish the inhibitory activity of 
MMI.9 Therefore, it would be interesting to know 
whether the replacement of the free hydrogen atom 
 
 
 
 
Figure 3. Tautomeric structures of MMI (1) and MSeI 
(2).6b 
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in MMI and MSeI by other substituents would lead 
to inactive substances. In view of this, we have  
synthesized a variety of thiones and selones having 
different substituents on both the nitrogen atoms 
present in the 5-membered ring. 
 In the present study, the required starting material, 
1-benzylimidazole, was synthesized conveniently 
from imidazole and benzylchloride. The treatment of 
imidazole with sodium hydride generated the corre-
sponding anion, which upon reaction with benzyl 
chloride afforded the expected compound. The ab-
straction of the proton from the imidazole nitrogen 
was found to be a clean reaction due to the stabiliza-
tion of the resulting anion by resonance contribution 
from the imidazole ring. The N,N-disubstituted deri-
vatives (7–10) are not accessible via the low-tempe-
rature lithiation route. Therefore, the thiones (7, 9) 
and selones (8, 10) were synthesized by a carbene 
route utilizing an imidazolium salt (scheme 1). The 
N,N-disubstituted derivatives were synthesized by 
treating 1-benzylimidazole with appropriate halides 
to produce the corresponding imidazolium salts, fol-
lowed by reactions with elemental sulfur or sele-
nium to afford the corresponding thiones or selones. 
In the first step of these reactions, the halides were 
added into the carbon–nitrogen double bond to give 
the corresponding N,N-substituted imidazolium salts. 
These salts were isolated and treated with a base 
(anhydrous potassium carbonate) and selenium or 
sulphur powder in dry methanol to give the corres-
ponding selones and thiones. In these reactions, the 
deprotonation of imidazolium salts by the base leads 
to an in situ generation of reactive carbenes, which 
in turn react with elemental sulfur or selenium to af-
ford the corresponding thiones or selones. These 
 
 
 
 
Scheme 1. Synthetic routes for compounds 7–10 via 
imidazolium salt/carbene. Reagents and conditions: (i) 
RX = CH3CH2Br for compounds 7 and 8; RX = PhCH2Cl 
for compounds 9 and 10; (ii) dry methanol, K2CO3, re-
flux; (iii) S or Se powder. 
compounds are readily soluble in dichloromethane 
and are thus easily separated from salt-like compo-
nents of the reaction mixture. In contrast to the sele-
nium analogue of MMI, the selenium derivatives 
synthesized in the present study are found to be sta-
ble in the presence of air and we did not observe any 
oxidation leading to the formation of diselenides. 
 We have shown in our previous studies that the 
replacement of the N-H moiety in MSeI by an N–Me 
or N–Bz group does not affect the nature of C–Se 
bond or the electron density around the selenium 
center.6g The computational and 77Se NMR spectro-
scopic studies on these compounds suggested that 
the molecules exist in their zwitterionic forms. The 
X-ray structure of 1,3-dimethyl-2(3H)-imidazole-
thione (figure 4, R = Me) was first reported by 
Ansel et al10 and based on the C–N and C–C bond 
lengths [C(thionyl)–N: 1⋅350 Å; C(ethylenic)–N: 1⋅41 Å 
and C=C: 1⋅31 Å] in the imidazole ring, they have 
proposed that the electronic structure of this com-
pound would best be represented by a resonance hy-
brid of structures I and IV (figure 4). Tomlin et al11 
on the other hand, re-evaluated the crystal structure 
of the same compound and proposed a more delocal-
ized zwitterionic structure V (figure 4). We have 
shown in our previous studies that the replacement 
of sulfur with selenium leads to an elongation of the 
C–E (E = S or Se) bond and generation of a more 
delocalized structure.6b,g The crystal structure of 2 
clearly showed that the two C–N bond lengths are 
almost identical (N1−C1: 1⋅350; N2–C1: 1⋅346).6g 
Therefore, the N,N-disubstituted thiones and selones 
that we synthesized in the present work can be con-
sidered as zwitterions having large negative charge 
on selenium and delocalized positive charge in the 
5-membered ring. 
 The crystal structures of compounds 7, 9 and 10 
(figure 5, table 1) reveal that these compounds do 
not have a true C=S or C=Se double bond. The C−S 
bond lengths in the thiones (7, 9) are found to be in 
the range of 1⋅674 to 1⋅683 Å, indicating much shorter 
bond lengths as compared with a C–S single bond 
(1⋅81 Å), but longer bond lengths when compared 
with a C=S double bond (1⋅61 Å).12 This suggests 
that the C−S bonds in the thiones may be treated as 
partial double bonds. Similarly, the C–Se bond in 10 
is found to be much weaker than a typical C–Se 
double bond and slightly stronger than a C–Se single 
bond. The shortening of the adjacent C–N bonds, a 
considerable elongation in the olefinic double bond 
(C=C bond) from a true C–C double bond and a sig-
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Figure 4. Possible tautomeric structures of N-N-disubstituted thiones (E = S) and 
selones (E = Se). 
 
 
Table 1. Crystallographic data for compounds 7, 9 and 10. 
 Compd 7 Compd 9 Compd 10 
 
Formula C12H14N2S C17H16N2S C17H16N2Se 
F
w
 218⋅3 276⋅4 326⋅3 
Crystal system Orthorhombic Monoclinic Monoclinic 
Space group P222 P2(1)/n P21 
a (Å) 6⋅7558(11) 7⋅9600(11) 7⋅4223(8) 
b (Å) 7⋅9881(13) 11⋅2967(17) 17⋅4649(18) 
c (Å) 21⋅9223(37) 16⋅3814(24) 11⋅6597(13) 
α (°) 90⋅00 90⋅00 90⋅00 
β (°) 90⋅00 92⋅636(3) 92⋅432(2) 
γ (°) 90⋅00 90⋅00 90⋅00 
V (Å3) 1183⋅06(3) 1471⋅49(4) 1510⋅08(3) 
Dcalc (mg m
–3) 1⋅23 1⋅25 1⋅43 
Z 4 4 4 
μ (mm–1) 0⋅243 0⋅210 2⋅478 
Reflections collected/unique 9231/2325 12623/3478 4438/4150 
Parameters 137 181 361 
Rint 0⋅025 0⋅042 0⋅014 
R
a 0⋅043 0⋅061 0⋅041 
Rw
b 0⋅097 0⋅162 0⋅087 
Goodness-of-fit on F2 1⋅071 1⋅112 0⋅987 
Δρmin and Δρmax (e.Å
–3) –0⋅121 and 0⋅262 –0⋅304 and 0⋅551 –0⋅345 and 0⋅411 
 
 
nificant shortening of the C(ethylenic)–N bonds in 
the imidazole ring in the selone 10 point to a delo-
calized zwitterionic structure as shown for MSeI. 
When we compare the structure of the thione 9 with 
that of its selenium analogue 10, it appears that C–
Se bond in compound 10 is more polarized than the 
C–S bond in compound 9, indicating a weak C-Se 
pi-overlap in the selenium compound. 
3.2 Inhibition of lactoperoxidase-catalysed  
oxidation 
The inhibition of peroxidase-catalysed oxidation re-
actions by thiourea compounds has been routinely used 
not only to determine the potency of clinically use-
ful anti-thyroid drugs, but also to understand the 
mechanism by which the drugs exert their anti-
thyroidal activity. Although the inhibition of thyroid 
peroxidase (TPO) and a related enzyme, lactoper-
oxidase (LPO) by anti-thyroid agents has been stud-
ied extensively in recent years, the mechanism of 
the inhibition of heme-peroxidases or the inhibition 
of peroxidase-catalysed oxidation and iodination re-
actions is still not clear. Magnusson et al suggested 
that the inhibition of TPO or LPO by the thiourea 
drugs may occur through competition with hydrogen 
peroxide for a common form of oxidized iodine.13 
Davidson et al proposed that anti-thyroid drugs 
block the iodination in vivo by reducing the oxidized 
iodide generated by the TPO, thus diverting it from 
the natural substrate tyrosyl residues.14 In contrast, 
Engler et al suggested that MMI and PTU exert their 
activity by reacting with the oxidized TPO heme 
group and thus inactivating the enzyme.15 It is also 
possible that the thiourea drugs are oxidized by the 
TPO/H2O2 system and the drugs in their oxidized 
forms may bind to the heme group of the enzyme. 
Taurog and Dorris, on the other hand, suggested that 
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the inhibition of iodination by compounds such as 
PTU involves a competition reaction between the 
drugs and tyrosine residues of thyroglobulin (Tg) for 
oxidized iodine.14,16 
 In the present study, we have carried out the en-
zyme inhibition experiments with lactoperoxidase 
(LPO, figure 6) since it is readily available in puri-
fied form.17 Furthermore, LPO has been shown to 
behave similarly to TPO with respect to iodination 
of thyroglobulin, the natural substrate, and other io-
dide acceptors.18 Edelhock et al have reported the 
inactivation of LPO by thiourea-based drugs using 
LPO-N-acetyltyrosylamide assay.19 We have em-
ployed 2,2′-azio-bis 3-ethyl-benthiazoline-6-sulpho-
nic acid (ABTS) and H2O2 as substrates to determine 
the half-maximal inhibitory concentration (IC50) of 
test compounds.6,20,21 The LPO activities at different 
concentration of MMI and MSeI are summarized in 
figure 7 and the corresponding IC50 values are given 
in table 2, respectively. 
 To obtain reliable IC50 values for compound 2 and to 
make a direct comparison with the sulfur analogue, 
 
 
 
Figure 5. X-ray crystal structures of compounds 7 (a), 
9 (b) and 10 (c). 
it is important to carry out the inhibition experi-
ments with the completely reduced species. We have 
observed that the selenium compound obtained di-
rectly from the reaction does not give any repro-
ducible results because it contains a mixture of 
MSeI and the corresponding diselenide. Therefore, 
we carried out the experiment with the reduced spe-
cies (2), which was obtained by reducing the dise-
lenide with NaBH4 in an aqueous solution and 
extracted in dichloromethane. However, compound 
2 generated by this method is reasonably stable to 
obtain reliable IC50 values. 
 
 
 
 
Figure 6. The active site structure of lactoperoxidase 
(PDB Code: 2GJ1).17 
 
 
 
Table 2. Inhibition of LPO activity by compounds 1–3, 
5, and 7–10. 
No. Compound IC50 (μM)
a 
 
1 MMI (1) 7⋅8 
2 MSeI
 
(2) 16⋅4 
3 PTU (3) 45.0 
4 MTU (5) 47⋅8 
5  7 Inactiveb 
6  8 12⋅3 
7  9 Inactiveb 
8 10 9⋅6 
aConcentration of the compound causing 50% inhibition. 
bThe compounds were inactive up to 100 μM and some 
solubility problems in the test buffer were observed above 
this concentration 
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Figure 7. Inhibition of LPO-catalysed oxidation of ABTS by MMI and MSeI at pH 7 and 30°C. The 
reaction mixture contained 0⋅5 μg/ml LPO, 1⋅4 mM ABTS, 0⋅067 M phosphate buffer (pH 7) and 
28⋅67 μM H2O2. The reaction was initiated by addition of H2O2. The initial formation of ABTS radical 
cation was monitored by an UV-vis spectrophotometer at 411 nm. 
 
 
 
 
Figure 8. A hypothetical model for the coordination of 
thiourea drugs to the Fe-center of TPO. 
 
 
 Similarly to the inhibition of LPO by MMI, the 
LPO activity decreases with an increase in the con-
centration of MSeI (figure 7). As expected, MMI 
exhibited high inhibitory activity towards LPO with 
an IC50 value of 7⋅8 μM, which is much lower than 
that observed with PTU and MTU. The selenium 
analogue (2) also inhibited LPO, and the IC50 value 
was found to be almost three times lower than that 
of PTU and MTU. The higher activity of MMI as 
compared with PTU and MTU is in agreement with 
the previous studies on the inhibition of TPO.15a,22 
Since the activation of the iron center in TPO must 
proceed through an interaction of Fe(III) with H2O2, 
the inhibition of TPO may occur through a competi-
tive coordination of the drug to iron, assisted by hy-
drogen bonding with a histidine residue of the TPO 
enzyme (figure 8).23 Under these conditions, MMI 
might compete more successfully than PTU with 
H2O2, because the hydrogen-bond (hard) basicity 
pkHB value of MMI (2⋅11) is much higher than that 
of PTU (~ 1⋅32).7g Similar to PTU, the methyl de-
rivative 6 (MTU) is also expected to be a weak inhibi-
tor of TPO. On the other hand, the nucleophilicity  
of the selenium moiety in compound 2 that exists 
predominantly in its zwitterionic form is expected
 
Figure 9. Plot of initial rates (vo) for the LPO-catalysed 
oxidation of ABTS vs concentration of MSeI (2). The 
reaction mixture contained 0⋅5 μg/ml LPO, 1⋅4 mM 
ABTS, 0⋅067 M phosphate buffer (pH 7) and 28⋅67 μM 
H2O2. The reaction was initiated with H2O2. The forma-
tion of ABTS radical cation was monitored at 411 nm. 
P N Jayaram et al 
 
152 
 
 
Figure 10. (a) Effect of compound 8 on the LPO-catalysed oxidation of ABTS. (b) Inhibition 
plots obtained by plotting the % control activity against the concentrations of compound 8. 
 
 
to be much higher than that of the sulfur analogue. 
However, the lower activity of MSeI as com- 
pared with MMI indicates that the selenium ana-
logue of MMI may inhibit LPO by a different 
mechanism. 
 As expected, the plot of initial rates (v0) vs con-
centration of MSeI shows that the rate of the reac-
tion decreases with increasing concentration of 
MSeI (figure 9). In all these cases, the LPO activity 
could be recovered by increasing the hydrogen per-
oxide concentration. These experimental obser-
vations support the conclusions made by Taurog et 
al that MSeI, unlike MMI, cannot act as an irre-
versible inhibitor of TPO. These observations also 
support the in vivo experiments, which showed that 
MMI is at least 50 times more potent than MSeI as 
an inhibitor of organic iodine formation in the thy-
roid.5 Crucially, the treatment of 2 with the se-
lenolate specific reagent, iodoacetic acid, abolished 
the inhibitory potency of 2, confirming that the oxi-
dation of the selenolate group by H2O2 is responsi-
ble for the inhibition. In contrast, the sulfur ana-
logue MMI was found to be less sensitive to the  
iodoacetic acid treatment, and this also confirms that 
the thiol (or thiolate) form of MMI is not only less 
predominant in solution but also less reactive as 
compared with the thione form. The decrease in the 
inhibitory activity of 2 upon iodoacetic acid treat-
ment can be ascribed to the formation of a protected 
selenide as a dead-end product. 
 In contrast to MMI, the thiones 7 and 9, which do 
not have any free N–H group do not inhibit the 
LPO-catalysed oxidation. Surprisingly, the replace-
ment of sulfur atoms in compounds 7 and 9 with sele-
nium (i.e. compounds 8 and 10) led to almost a 
complete inhibition of LPO activity with IC50 values 
of 12.3 μM and 9⋅6 μM, respectively, which are 
lower than that of MSeI (16⋅4 μM). Also, these two 
selenium compounds are much more active than the 
2-thiouracil derivatives. The effect of 8 on the LPO-
catalysed oxidation of ABTS is summarized in fig-
ure 10a and the inhibition plot for 8 is shown in fig-
ure 10b. Although compounds 8 and 10 lack the 
essential N–H group, the higher inhibitory activity 
of these compounds as compared with their sulfur 
analogues can be ascribed to the existence of 8 and 
10 in zwitterionic structures where the selenium moi-
ety acts as a selenolate rather than a selone. Simi-
larly to MSeI (2), the negatively charged selenium 
moiety may scavenge the H2O2 substrate effectively 
present in the model system (ABTS assay) or this 
compound may interfere with the oxidized LPO spe-
cies, leading to a reversible inactivation. 
4. Conclusion 
In this paper, we have described the keto-enol type 
tautomerism in anti-thyroid drugs and their selenium 
analogues. The present study supports our previous 
observations that the anti-thyroid agent methimazole 
(MMI) exists predominantly in its thione form, 
whereas its selenium analogue exists in a zwitteri-
onic form with a large negative charge on selenium. 
We have studied the importance of thione/thiol and 
selone/selenol tautomerism on the inhibition of per-
oxidase-catalysed reactions by using N,N-disubstitu-
ted thiones and selones. These studies reveal that the 
presence of a free N-H moiety in the sulfur-based 
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compounds is essential for an efficient inhibition. In 
contrast to the thiones, the N,N-disubsituted selones 
were found to be efficient inhibitors of LPO-catalysed 
oxidation, indicating that the free N-H moiety is not 
required for the inhibition.  
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